Q-omics provides the consensus-scored RPS2P45 profile across patient tissues and cancer cell-line models. RPS2P45 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RPS2P45 is differentially expressed in 8, with the highest sampling consensus in HNSC. Additionally, RPS2P45 RNA expression shows 7,572 significant gene co-expression associations, with the highest sampling consensus in LAML. Together, these results highlight ACC, HNSC, and LAML as cancer lineages where RPS2P45 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS2P45 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS2P45 survival associations across molecular data types. RPS2P45 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS2P45 RNA expression–survival associations across cancer types. High RPS2P45 expression shows unfavorable associations in ACC, LIHC, THCA and KIRC, but favorable associations in LAML and ESCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RPS2P45 RNA expression.
This table summarizes RPS2P45 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for RPS2P45. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS2P45 shows lower tumor expression in LUSC, KICH and LUAD and higher tumor expression in HNSC, KIRC and COAD. The HNSC box plot shows higher RPS2P45 RNA expression in tumor versus normal tissue (log2 FC = +0.049, t-test p = .004).
This table shows molecular features associated with RPS2P45 in patient tissues and cancer cell lines. In patient samples, RPS2P45 shows the broadest associations at the RNA and protein expression levels, with LAML recurring as the lineage with the largest associated feature set. In cancer cell lines, RPS2P45 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in NCI60_ALL.
